op-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY INTRODUCTION The development of mutant BRAF and of MEK1/2 inhibitors has markedly improved treatment of advanced BRAF-mutant melanoma [ 1 - 2 ] showing highly significant effects on progression-free and/or overall survival in several phase III trials, in comparison to chemotherapy [ 3 ].
← all excerpts
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.
1
—
—